TSX:NVCN (Canada)
Business Description
Neovasc Inc
NAICS : 339112
SIC : 3741
13562 Maycrest Way, Suite 5138, Richmond, BC, CAN, V6V 2J7
Description
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.54 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.29 | |||||
| Debt-to-EBITDA | -0.4 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -10.07 | |||||
| Beneish M-Score | -3.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -68.5 | |||||
| 3-Year EBITDA Growth Rate | 83.2 | |||||
| 3-Year EPS without NRI Growth Rate | 82.9 | |||||
| 3-Year FCF Growth Rate | 70.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 97.9 | |||||
| 9-Day RSI | 92.64 | |||||
| 14-Day RSI | 84.7 | |||||
| 6-1 Month Momentum % | -42.18 | |||||
| 12-1 Month Momentum % | -70 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.88 | |||||
| Quick Ratio | 12.5 | |||||
| Cash Ratio | 11.86 | |||||
| Days Inventory | 796.46 | |||||
| Days Sales Outstanding | 84.26 | |||||
| Days Payable | 835.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -189 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.06 | |||||
| Operating Margin % | -950.61 | |||||
| Net Margin % | -1212.09 | |||||
| ROE % | -56.9 | |||||
| ROA % | -44.47 | |||||
| ROIC % | -182.99 | |||||
| ROC (Joel Greenblatt) % | -3718.04 | |||||
| ROCE % | -46.41 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.1 | |||||
| PB Ratio | 0.5 | |||||
| Price-to-Tangible-Book | 0.5 | |||||
| EV-to-EBIT | 0.32 | |||||
| EV-to-EBITDA | 0.33 | |||||
| EV-to-Revenue | -3.79 | |||||
| EV-to-FCF | 0.4 | |||||
| Price-to-Median-PS-Value | 0.78 | |||||
| Price-to-Net-Current-Asset-Value | 0.69 | |||||
| Price-to-Net-Cash | 0.79 | |||||
| Earnings Yield (Greenblatt) % | 312.5 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 3.409 | ||
| EPS (TTM) (C$) | -15.083 | ||
| Beta | 1.99 | ||
| Volatility % | 58.8 | ||
| 14-Day RSI | 84.7 | ||
| 14-Day ATR (C$) | 0.262682 | ||
| 20-Day SMA (C$) | 8.494 | ||
| 12-1 Month Momentum % | -70 | ||
| 52-Week Range (C$) | 6 - 27 | ||
| Shares Outstanding (Mil) | 2.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neovasc Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||